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e102 Letterspapillomavirus types was negative in that case,
whereas staining with the proliferation markers
Ki-67 and cytokeratin 5/6 showed dramatically
increased labeling of basilar and suprabasilar kera-
tinocytes. Another report described 5 patients with
intertriginous erythema and hyperpigmented pap-
ules that began 7 to 30 days after the first palifermin
dose. Pathology revealed a prominent granular layer
with coarse granules in biopsy samples, features also
seen in our case. In addition, they demonstrate
up-regulation of filaggrin, a well-described effect of
keratinocyte growth factor.6
Although our patient’s eruption was not
predominantly intertriginous, the timing, clinical
morphology, and histopathologic findings are
consistent with palifermin-associated papules.
Based on immunohistochemical studies performed
in the aforementioned cases, it seems reasonable
to conclude with those investigators that the
papular eruption is likely a result of palifermin’s
proliferative effect on epithelial tissues.2,6 The
vast majority of cutaneous reactions caused by
palifermin have been benign, minimally symptom-
atic, and self-limited, with resolution of lesions soon
after stopping the medication. Three days after
completion of palifermin, our patient already
demonstrated partial regression of the lesions,
although we did recommend a mid-potency topical
corticosteroid for relief of pruritus that improved his
symptoms.
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A 52-year-old man with bullous pemphigoid
and bullous cystitis
To the Editor: A 52-year-old man with a medical
history of psoriasis and bullous pemphigoid (BP)
presented with a flare of his BP (Fig 1), which
was first diagnosed in 2003 and confirmed by
indirect immunofluorescence on salt-split skin. On
examination, he had erosions and bullae on the
bilateral lower extremities without evidence of
oral or anogenital mucosal involvement. In
addition, the patient stated that he recently had
a cystoscopy with bladder biopsies for ongoing
dysuria, frequency, and microhematuria, which
started 10 months prior. On cystoscopy, the
bladder was noted to have numerous bullae.
Biopsy specimen was obtained of the perilesional
epithelium in the bladder, which demonstrated
numerous eosinophils and a subepithelial split
(Fig 2). At the time of the cystoscopy, he was not
taking any medications that could account for the
bladder inflammation nor did his urinalysis or
urine culture show evidence of infection. Because
of previous resolution of his BP with Enbrel (as
was initially prescribed for his psoriasis), the
patient was restarted on Enbrel (50 mg) twice
weekly for 3 months to be used in conjunction
with clobetasol 0.05% ointment twice daily. At his
follow-up appointment 4 months later, his BP was
clear and his urologic symptoms had completely
abated.
To our knowledge, symptomatic involvement of
the bladder in BP has not been described to
date; however, expression of BP180 has been
demonstrated in the transitional epithelium of
the bladder by indirect immunofluorescence.1 In
addition, BP230 has been demonstrated by
immunofluorescence in rat bladder tumor cell line.2
Despite this, the only bladder involvement in BP was
demonstrated in asymptomatic patients based on
Fig 1. A 52-year-old man with bullous pemphigoid
demonstrating numerous large, tense bullae and urticarial
plaques on the chest.
Fig 2. Bladder tissue from 52-year-old man with bullous
pemphigoid and cystitis showing many eosinophils
(broad arrow) and a subepithelial split (asterisk).
(Hematoxylin-eosin stain; original magnification: 3100.)
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newly diagnosed autoimmune bullous dermatoses,
including 4 individuals with BP, underwent
cystoscopy; of these patients, 13 had lower urinary
tract lesions. On pathology 2 patterns predominated:
nonkeratinizing squamous metaplasia and mucosal
inflammation of the bladder base. Among patients
with BP, the pathologic pattern of mucosal inflam-
mation prevailed (P ¼ .003).3
Limitations of this case include that the
subepithelial split on bladder biopsy specimen
could have been caused by trauma from the biopsy;
the biopsy specimen did however demonstrate
numerous eosinophils, which would be consistent
with BP. Direct immunofluorescence studies were
not performed on the bladder tissue. In addition, a
follow-up cystoscopy was not available to evaluate
whether the bladder lesions had cleared. An
interesting consideration is the atypical nature of
this patient’s BP. Given his age of onset (42 years),
concomitant psoriasis, and response to Enbrel (as
was initially used to treat his psoriasis, but also helped
resolve his BP), it is possible that this is a variant of
pemphigoid that is not yet described in the literature.Despite these limitations, given the cystoscopy
findings of bullae by the urologist, pathology
of the bladder epithelium on biopsy, and
that resolution of the patient’s urinary symptoms
coincided with resolution of his cutaneous
bullae, and typical immunofluorescence pattern
on salt-split skin for BP, this case seems to be most
consistent with symptomatic bladder involvement
of BP.
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Successful topical adapalene treatment for the
facial lesions of an adolescent case of
epidermolytic ichthyosis
To the Editor: Epidermolytic ichthyosis (EI) is a
keratinopathic ichthyosis that is characterized by
generalized multiple blisters and erosions with
erythroderma at birth. EI is caused by autosomal
dominant rarely recessive mutations in the keratin
1 gene (KRT1) or the keratin 10 gene (KRT10).
Their mutations lead to cytoskeletal fragility in
the upper epidermis. Here we report the successful
use of topical adapalene for treating a patient
with EI.
A 16-year-old Japanese male adolescent was
given the diagnosis of EI at birth. He was born with
erythrodermic skin, blisters, and erosions on the
whole body. As previously reported,1 mutation
analysis using the patient’s genomic DNA samples
revealed the heterozygous missense mutation
c.457C[G (p.Leu153Val) in KRT10. During the first
